Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USL255 open-label extension in refractory partial-onset seizures
2009-017904-95Phase 3Completed
- Sponsor
- Upsher-Smith Laboratories
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of topiramate in focal-onset epileptic seizures and focal to bilateral tonic-clonic seizure, sponsored by Upsher-Smith Laboratories. Primary endpoint: Safety and tolerability of USL255. Started Apr 2010; status: completed.
02
Drugs
topiramate
03
Conditions
focal-onset epileptic seizuresfocal to bilateral tonic-clonic seizure
Beyond the preview
Go deeper on 2009-017904-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017904-95.